Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunity Evaluation of a Covid-19 aAPC Vaccine
NCT04299724Phase 1Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- Cell Therapies, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial in coronavirus disease 2019 (COVID-19), sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoints: Frequency of vaccine events, Frequency of serious vaccine events and 1 more. Started Jun 2026; status: terminated.
02
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04299724.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04299724.